Video Highlights
1:18 Kimberly Green, PhD
2:22 S. Wilson Beckham, PhD, MPH, MA
3:44 Renee Heffron, PhD, MPH
4:28 Laura Rusie, ScM
The Potential Addition of Long-Acting Injectables for PrEP
What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Do you think the addition of long-term acting injectables for PrEP will lead to greater utilization of it?
We interviewed Kimberly Green, PhD, global program director, Primary Health Care, PATH; S. Wilson Beckham, PhD, MPH, MA, assistant scientist, Department of Health, Behavior and Society, and Department of International Health—Social & Behavioral Sciences, Johns Hopkins Bloomberg School of Public Health; Renee Heffron, PhD, MPH, associate professor, Global Health, associate professor, Epidemiology, Department of Global Health, University of Washington; and Laura Rusie, ScM director of Data, Evaluation, and Epidemiology, Howard Brown Health.
Watch the video to hear their insights.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
Related Content
